Venus Medtech Stock Performance
| VMTHF Stock | USD 0.27 0.00 0.00% |
The entity has a beta of 2.76, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Venus Medtech will likely underperform. At this point, Venus Medtech has a negative expected return of -0.82%. Please make sure to validate Venus Medtech's jensen alpha, kurtosis, as well as the relationship between the Kurtosis and relative strength index , to decide if Venus Medtech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Venus Medtech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's technical indicators remain nearly stable which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 2.7 B | |
| Total Cashflows From Investing Activities | -653 M |
Venus |
Venus Medtech Relative Risk vs. Return Landscape
If you would invest 52.00 in Venus Medtech on September 30, 2025 and sell it today you would lose (25.00) from holding Venus Medtech or give up 48.08% of portfolio value over 90 days. Venus Medtech is currently producing negative expected returns and takes up 5.5681% volatility of returns over 90 trading days. Put another way, 49% of traded pink sheets are less volatile than Venus, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Venus Medtech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Venus Medtech's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Venus Medtech, and traders can use it to determine the average amount a Venus Medtech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1468
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VMTHF |
Based on monthly moving average Venus Medtech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Venus Medtech by adding Venus Medtech to a well-diversified portfolio.
Venus Medtech Fundamentals Growth
Venus Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Venus Medtech, and Venus Medtech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Venus Pink Sheet performance.
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0486 | |||
| Profit Margin | (1.19) % | |||
| Operating Margin | (1.18) % | |||
| Current Valuation | 550.27 M | |||
| Shares Outstanding | 441.01 M | |||
| Price To Book | 1.08 X | |||
| Price To Sales | 2.28 X | |||
| Revenue | 415.86 M | |||
| EBITDA | (324.03 M) | |||
| Cash And Equivalents | 2.96 B | |||
| Cash Per Share | 6.75 X | |||
| Total Debt | 70.78 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 10.09 X | |||
| Cash Flow From Operations | (456.92 M) | |||
| Earnings Per Share | (0.13) X | |||
| Total Asset | 5.11 B | |||
About Venus Medtech Performance
By analyzing Venus Medtech's fundamental ratios, stakeholders can gain valuable insights into Venus Medtech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Venus Medtech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Venus Medtech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Venus Medtech Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company was founded in 2009 and is headquartered in Hangzhou, the Peoples Republic of China. Venus Medtech operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 905 people.Things to note about Venus Medtech performance evaluation
Checking the ongoing alerts about Venus Medtech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Venus Medtech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Venus Medtech generated a negative expected return over the last 90 days | |
| Venus Medtech has high historical volatility and very poor performance | |
| Venus Medtech has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 415.86 M. Net Loss for the year was (373.64 M) with profit before overhead, payroll, taxes, and interest of 324.34 M. | |
| Venus Medtech has accumulated about 2.96 B in cash with (456.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.75, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 22.0% of the company outstanding shares are owned by insiders |
- Analyzing Venus Medtech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Venus Medtech's stock is overvalued or undervalued compared to its peers.
- Examining Venus Medtech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Venus Medtech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Venus Medtech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Venus Medtech's pink sheet. These opinions can provide insight into Venus Medtech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Venus Pink Sheet analysis
When running Venus Medtech's price analysis, check to measure Venus Medtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Venus Medtech is operating at the current time. Most of Venus Medtech's value examination focuses on studying past and present price action to predict the probability of Venus Medtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Venus Medtech's price. Additionally, you may evaluate how the addition of Venus Medtech to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |